Why Summit Therapeutics Rocketed Over 60% Today
The Motley FoolThe company’s new lung cancer treatment could unseat Merck’s Keytruda in the $50 billion-plus lung cancer treatment market.
The company’s new lung cancer treatment could unseat Merck’s Keytruda in the $50 billion-plus lung cancer treatment market.